FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (opens in new tab)

Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies